EP1948257A1 - Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes - Google Patents

Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes

Info

Publication number
EP1948257A1
EP1948257A1 EP06818566A EP06818566A EP1948257A1 EP 1948257 A1 EP1948257 A1 EP 1948257A1 EP 06818566 A EP06818566 A EP 06818566A EP 06818566 A EP06818566 A EP 06818566A EP 1948257 A1 EP1948257 A1 EP 1948257A1
Authority
EP
European Patent Office
Prior art keywords
shaped body
gelatin
body according
stretching
crosslinking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06818566A
Other languages
German (de)
English (en)
Other versions
EP1948257B1 (fr
Inventor
Michael Ahlers
Melanie Rupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gelita AG
Original Assignee
Gelita AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gelita AG filed Critical Gelita AG
Publication of EP1948257A1 publication Critical patent/EP1948257A1/fr
Application granted granted Critical
Publication of EP1948257B1 publication Critical patent/EP1948257B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/222—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/502—Plasticizers

Definitions

  • Shaped body based on a crosslinked, gelatin-containing material, process for their preparation and their use
  • the present invention relates to moldings based on a crosslinked, gelatin-containing material. Furthermore, the invention relates to a method for producing such shaped bodies.
  • the invention also relates to the use of these moldings in the medical field, in particular for the production of implants.
  • tissue implants which are constructs of a resorbable carrier material and living cells (tissue engineering). These are used to treat damaged tissues and organs, in particular for the regeneration of skin or cartilage.
  • Such materials must meet a number of properties in order to be used successfully in the medical field. On the one hand, they must have sufficient strength to allow damage-free handling and to protect growing cells in the body against mechanical stress. At the same time, the material should be flexible enough to adapt to the shape of the body site to be treated.
  • gelatin is well suited as a base material for fulfilling the stated conditions. Gelatin can be completely absorbed by the body and thus has an advantage over other materials such as chitosan, alginate, agarose and hyaluronic acid. In contrast to the related material collagen, gelatin is available in high purity and with a reproducible composition and is free of immunogenic telopeptides, which can trigger defense reactions of the body.
  • the gelatin In order to achieve a sufficiently long stability of the moldings under physiological conditions, the gelatin generally has to be crosslinked chemically or enzymatically.
  • the residue-free absorbability is not impaired, but the respective absorption time can be adjusted individually by the degree of crosslinking.
  • the object of the present invention is to provide moldings based on gelatin which have both high mechanical strength and sufficient flexibility.
  • a shaped body based on a crosslinked, gelatin-containing material wherein the shaped body is stretched, so that the gelatin molecules are oriented at least partially in a preferred direction, and wherein the material comprises a plasticizer.
  • moldings based on gelatin which on the one hand comprise a plasticizer and on the other hand are crosslinked, can be stretched particularly well.
  • the mechanical properties of the moldings in particular their tear strength and elongation at break, can be markedly improved.
  • the gelatin-containing material on the basis of which the molded article is produced is preferably formed predominantly of gelatin. These include, in particular, gelatin contents of 60% by weight or more, preferably 75% by weight or more.
  • the material may contain, for example, other biopolymers such as alginates or hyaluronic acid in order to adapt the property profile of the shaped bodies more specifically to a specific application.
  • the preferred starting material is gelatin having a particularly low content of endotoxins. set.
  • Endotoxins are metabolic products or fragments of microorganisms found in the animal raw material.
  • the endotoxin content of gelatin is expressed in international units per gram (IU / g) and determined according to the LAL test described in the fourth edition of the European Pharmacopoeia (Ph. Eur. 4).
  • the endotoxin content of gelatin can be drastically reduced by certain measures in the manufacturing process.
  • measures include, first and foremost, the use of fresh raw materials (e.g., pork rind) to avoid storage times, the thorough cleaning of the entire production line just prior to the start of gelatine production, and, if necessary, the replacement of ion exchangers and filtration systems at the production line.
  • the gelatin used in the present invention preferably has an endotoxin content of 1,200 I.U./g or less, more preferably 200 I.U./g or less. Optimally, the endotoxin content is 50 I.U./g or less, each determined according to the LAL test. In comparison, some commercially available gelatins have endotoxin levels of over 20,000 I.U./g.
  • the material comprises, in addition to the gelatin, at least one plasticizer, which increases the flexibility of the molded article and its Stretchability is significantly improved.
  • plasticizers for example, glycerol, oligoglycerols, oligoglycols and sorbitol are suitable, with glycerol being most preferred.
  • the desired flexibility of the molded article can be controlled by the amount of plasticizer.
  • the proportion of plasticizer in the material is preferably 12 to 40% by weight. In this case, proportions of 16 to 25% by weight are particularly advantageous.
  • the stretched shaped body is preferably monoaxially stretched. This defines a preferred direction along which the gelatin molecules are at least partially oriented.
  • the moldings according to the invention have a high mechanical strength, in particular tensile strength.
  • the moldings according to the invention preferably have a tensile strength of 40 N / mm 2 or more, more preferably 60 N / mm 2 or more, in each case measured in the stretching direction.
  • the shaped bodies surprisingly also have a high elongation at break (yield strength), in particular in the stretching direction.
  • the elongation at break of the shaped body is preferably 30% or higher, more preferably 50% or higher, in each case measured in the stretching direction.
  • both the gelatin and other suitable components of the material may be crosslinked in the molding. However, it is preferred that in particular the gelatin is crosslinked.
  • the crosslinking can be a chemical crosslinking.
  • any crosslinking agent is suitable, the linkage of the individual gelatin molecules causes each other.
  • Preferred crosslinking agents are aldehydes, dialdehydes, isocyanates, diisocyanates, carbodiimides and alkyldihalogenide.
  • Particularly preferred is formaldehyde, which simultaneously causes a sterilization of the molding.
  • the material is enzymatically crosslinked.
  • the crosslinking agent used here is preferably the enzyme transglutaminase, which effects a linkage of the glutamine and lysine side chains of proteins, in particular also of gelatin.
  • shaped bodies according to the invention can have surprisingly long lifetimes under physiological conditions, wherein these can be adjusted very selectively by the degree of crosslinking.
  • shaped bodies according to the invention may remain stable under standard physiological conditions, for example for more than one week, more than two weeks or more than four weeks.
  • stability is to be understood here as meaning that the shaped body essentially retains its original shape both when stored in the dry state and during the stated period of time under physiological standard conditions, and only then is structurally hydrolytically degraded to a considerable extent.
  • Physiological conditions to which the moldings are exposed when used to make implants are primarily characterized by temperature, pH and ionic strength. Appropriate conditions may in vitro by incubation in PBS buffer (pH 7.2, 37 0 C) are simulated to various molded articles in view of their time-dependent Stability to test and compare their behavior (hereinafter referred to as standard physiological conditions).
  • the mechanical strength of the moldings of the invention can be additionally increased by the addition of a reinforcing material.
  • the reinforcing substances should be physiologically compatible and best also absorbable.
  • the stability of the shaped bodies against absorption mechanisms can be influenced to a certain extent.
  • the absorption stability of the reinforcing materials can be selected independently of the components of the gelatin-containing material.
  • the reinforcing materials show a marked improvement in the mechanical properties of the moldings.
  • the reinforcing materials can be selected from particulate and molecular reinforcing materials as well as mixtures thereof.
  • the fibers are preferably selected from polysaccharide and protein fibers, in particular collagen fibers, silk and cotton fibers, as well as from polylactide fibers and mixtures thereof.
  • molecular reinforcing agents are also suitable for improving the mechanical properties and, if desired, also the absorption stability of the molding.
  • Preferred molecular reinforcing agents are, in particular, polylactide polymers and their derivatives, cellulose derivatives and chitosan and its derivatives.
  • the molecular reinforcing substances can also be used as mixtures.
  • this is present as a film.
  • films based on a cross-linked gelatin-containing material can be widely used for covering and / or supporting damaged tissue, for colonizing with cells and for producing combination materials in connection with shaped bodies having a cell structure, e.g. Sponges, are used.
  • the thickness of the films according to the invention is preferably 20 to 500 ⁇ m, most preferably 50 to 250 ⁇ m.
  • a further preferred embodiment of the shaped body according to the invention relates to a hollow cylinder.
  • Such hollow cylinders can be used, inter alia, as Nervenleitschienen. These are implants that allow the regeneration of severed nerve cords by growing a single nerve cell along the cavity of the nerve guide.
  • Hollow cylinders according to the invention can be stretched both in the longitudinal direction and in the circumferential direction. On the respective production of such hollow cylinder will be discussed in detail below.
  • the inner diameter can be adapted to the respective requirements, e.g. to the dimensions of nerve cells when using the hollow cylinder as a nerve guide.
  • the hollow cylinder may have an inner diameter of 300 to 1500 microns, preferably from 900 to 1200 microns.
  • the average wall thickness of the hollow cylinder is preferably in the range of 140 to 250 microns.
  • the object of the present invention is further to provide a method by which moldings based on gelatin having improved mechanical properties can be produced.
  • the stretching takes place after the gelatin-containing material has been at least partially crosslinked. This sequence gives better results than stretching the molded article prior to cross-linking according to the prior art (Bigi et al. (1998) Biomaterials 19, 2335-2340, supra).
  • the gelatin-containing material used in step a) is preferably predominantly formed from gelatin. These include, in particular, gelatin contents of 60% by weight or more, preferably 75% by weight or more. In addition, the material, as described above, may contain other components.
  • gelatin of various origin and quality can be used; however, in view of a medical application, the use of endocoxin-deficient gelatin as described above is preferred.
  • the gelatin concentration in the solution in step a) can be from 5 to 45% by weight, preferably from 10 to 30% by weight.
  • the material in step a) additionally comprises a plasticizer.
  • a plasticizer are, for example, glycerol, oligoglycerols, oligoglycols and sorbitol, with glycerol being the most preferred.
  • the proportion of plasticizer in the material is 12 to 40% by weight. Most preferred are proportions of 16 to 25 wt.%.
  • the shaped body formed in step c) is preferably at least partially dried before being drawn (step d)), preferably to a residual moisture content of less than 20% by weight, in particular 15% by weight or less.
  • the molded article is converted into a thermoplastic state immediately before stretching (step d)) by increasing the temperature and / or the water content.
  • This can be done, for example, by exposing the molding to hot steam.
  • the stretching of the shaped bodies is advantageously carried out with a draw ratio of 1.4 to 8, with a draw ratio of up to 4 being preferred.
  • step d) is carried out up to four weeks after step c).
  • the strength of the molded body according to the invention can be increased in part significantly.
  • step d) is carried out three to seven days after step c).
  • a further embodiment of the method according to the invention comprises a further step e), in which the Matrial contained in the stretched shaped body is additionally crosslinked.
  • the gelatin and / or another suitable component of the material can be crosslinked. In both cases, in particular, the gelatin is preferably crosslinked.
  • the advantage of a two-stage cross-linking is basically that a high degree of cross-linking and concomitantly long degradation times can be achieved. This can not be achieved to the same extent by a one-step process with an increase in the concentration of crosslinking agent, since excessive crosslinking of the dissolved material makes it impossible to process it and form it.
  • a crosslinking of the material is not suitable exclusively after the production of the molded article, since this crosslinks more strongly at the externally accessible interfaces than in the inner regions of the molded article, which is reflected in an inhomogeneous degradation behavior.
  • the stretching of the shaped body according to the invention between the two crosslinking steps is particularly advantageous because the molecules in the partially crosslinked material still have sufficient freedom of movement and can thus orient themselves at least partially along a preferred direction.
  • the second crosslinking (step e)) may be carried out by the action of an aqueous solution of a crosslinking agent, but it is preferable to use a gaseous crosslinking agent.
  • steps b) and, if appropriate, e) it is possible to use identical or different crosslinking agents, with preferred chemical or enzymatic crosslinking agents already being used in conjunction with the molding compound according to the invention. body were described. Particularly preferred is formaldehyde, especially for the eventual second cross-linking step in the gas phase, since the shaped body can be sterilized simultaneously by formaldehyde. In this case, the action of formaldehyde on the molding can be supported by a steam atmosphere.
  • the crosslinking agent is preferably added to the solution in step b) in an amount of 600 to 5,000 ppm, preferably 2,000 to 4,000 ppm, based on the gelatin.
  • both the mechanical strength of the moldings produced and their life can be adjusted under physiological conditions in a simple manner.
  • shaped bodies can be obtained which, on the one hand, can be treated under physiological conditions, e.g. remain stable for more than one week, longer than two weeks or more than four weeks, and on the other hand meet the requirements of cell compatibility and absorbability.
  • the shaped body is a film.
  • films can be made by casting or extruding the solution in step c).
  • the shaped body is a hollow cylinder.
  • Hollow cylinders can also be produced by extruding the solution in step c).
  • a production of hollow cylinders by a uniform application of the solution in step c) to the surface of a cylinder, in particular by short-term immerse the cylinder in the solution.
  • drying the solution creates a hollow cylinder, which can be removed from the cylinder.
  • Another preferred production method for hollow cylinders comprises rolling a film into a single-layer or multi-layer hollow cylinder.
  • the connection of the film to a closed hollow cylinder can e.g. be effected by the fact that the film is moist when rolled up and thereby glued.
  • the foil may be sealed by means of an adhesive, e.g. Gelatin, be connected.
  • the hollow cylinder is first formed by rolling up an unstretched film (steps a) to c)) and then stretched in the longitudinal direction (step d)), wherein the inner diameter is reduced (see above). In this way, hollow cylinders produced by dipping can be stretched.
  • a film is produced and stretched (steps a) to d)) and only then rolled up into a hollow cylinder.
  • the rolling can take place either parallel or perpendicular to the direction of stretching, whereby hollow cylinders are obtained with an increased tensile strength in the longitudinal direction or in the circumferential direction.
  • one or the other variant may be preferred.
  • a rolling up of films perpendicular to the direction of stretching is advantageous, in particular in the case of fiber-reinforced films, since in this case the fibers are oriented at least partially along the circumferential direction of the hollow cylinder.
  • a deratige fiber orientation can counteract a tearing of the suture.
  • the process according to the invention is particularly suitable for the production of the moldings according to the invention described above. Further advantages of the production process thus result from the description of the shaped bodies according to the invention.
  • the invention further relates to the use of the shaped bodies described for use in the human and veterinary medical field and for the production of implants.
  • a use according to the invention relates firstly to the production of wound dressings from the above-described moldings. These can be used in the treatment of wounds or internal or external bleeding, e.g. in operations.
  • the absorption of the shaped body takes place after an individually adjustable time, preferably by the choice of the production conditions.
  • the shaped bodies according to the invention are outstandingly suitable for colonization with mammalian cells, i. with human or animal cells, are suitable.
  • a shaped body is treated with a suitable nutrient medium and then the cells, e.g. Fibroblasts or chondrocytes, seeded on it. Due to the stability of the material, cells can grow and proliferate in vitro for several weeks.
  • the invention further relates to implants, in particular tissue implants, which comprise a shaped body according to the invention and cells applied or cultivated thereon, as described above.
  • the implants according to the invention are used for the treatment of tissue defects, for example skin or cartilage defects, wherein the seeded cells, for example, before the patient can be removed.
  • tissue defects for example skin or cartilage defects
  • the shaped body provides the forming tissue with protection against mechanical stress, and the formation of the cell's own extracellular matrix is made possible.
  • Both the high mechanical strength and the adjustable absorption time of the mold body according to the invention prove to be a particular advantage. With the help of long-lived materials that have a resorption time of more than four weeks, even large-area defects or defects in tissue types with slow cell growth can be treated.
  • the invention relates to a nerve guide, comprising a molding according to the invention in the form of a hollow cylinder. Particular advantages and embodiments of such nerve guide rails have already been described in detail above.
  • FIG. 1 Tensile / elongation diagram of moldings according to the invention in the form of films with different degree of crosslinking during stretching after a storage time of three days;
  • FIG. 2 Tensile / elongation diagram of moldings according to the invention in the form of films with different degree of crosslinking during stretching after a storage time of seven days;
  • FIG. 3 Tensile / elongation diagram of moldings according to the invention in FIG.
  • FIG. 4 Tensile / elongation diagram of moldings according to the invention in the form of films having a different proportion of plasticizer when drawn after a storage time of three days;
  • FIG. 5 Tensile / elongation diagram of moldings according to the invention in the form of films with a different proportion of plasticizer when drawn after a storage time of seven days;
  • FIG. 6 Tensile / elongation diagram of moldings according to the invention in the form of films with a different proportion of plasticizer when drawn after a storage time of 28 days;
  • FIG. 7 photographic representation of hollow cylinders according to the invention.
  • FIG. 8 light micrograph of a hollow cylinder according to the invention in cross section.
  • Example 1 Preparation and properties of stretched and unstretched films with different degrees of crosslinking
  • various films were prepared based on a material containing constant amounts of about 71% by weight of gelatin and about 29% by weight of plasticizer.
  • the different amounts of crosslinking agent were between 1,000 and 4,000 ppm (in each case based on the amount of gelatin).
  • 20 g Pork skin gelatin with a Bloom strength of 300 g dissolved as a plasticizer at 60 0 C in a mixture of 72 g water and 8 g of glycerol per batch.
  • the films produced were removed from the PE support.
  • the thickness of the films was about 220 microns.
  • the films were softened under the action of hot steam, elongated in this thermoplastic state in one direction to the stretching limit and overnight at one at a temperature fixed at 23 ° C. and a relative humidity of 45%.
  • the stretching ratios were in a range of approx. 2 to 4.
  • the first two digits represent the approach after which the film was made, while the third digit for the storage time of the film is before stretching (three, seven or 28 days). Stretched films are identified by the letter V in front of the last digit.
  • FIG. 1 shows the tensile / elongation diagram of the films stretched after three days and of the unstretched comparative films which have been stored for three days under the same conditions. A comparison of the curves with each other first shows that the tear strength of the inventively stretched films increases significantly with the increase in the content of crosslinking agent.
  • FIG. 2 shows the tensile / elongation diagram of the films stretched after seven days and the corresponding comparative films. The higher tensile strength of the films achieved by stretching is also clearly recognizable here.
  • FIG. 3 shows the mechanical properties of the films stretched after 28 days and of the corresponding comparative films.
  • the tensile / elongation diagrams have been included here only for slides according to approaches 1-1, 1-3 and 1-4.
  • Example 2 Preparation and properties of stretched and unstretched films with different levels of plasticizer
  • This example relates to crosslinked gelatin-based films having a constant crosslinking agent content of 2,000 ppm (based on the amount of gelatin).
  • the material for the films comprised different amounts of plasticizer between about 17% by weight and about 33% by weight.
  • FIG. 4 shows the tensile / elongation diagrams of the films according to the invention, which were drawn after a storage time of three days, and the corresponding unstretched comparative films.
  • the tensile / elongation diagrams of the films stretched after seven days in Figure 5 show qualitatively the same results as in three days stretching.
  • the tear resistance of the inventively stretched films is increased significantly by the longer storage time, in part, which is primarily due to the above-described continued running of the crosslinking reaction should be due. Also on the elongation at break the longer storage has a positive influence.
  • FIG. 6 shows the tensile / elongation diagrams of the films with a storage time of 28 days, in which case only the stretched and unstretched films of the lugs 2-1, 2-2 and 2-4 were measured.
  • the curves have a very similar course, the tear strengths of the stretched films are even slightly lower than in the seven-day storage. This indicates that there is an optimum for storage time, which should be dependent on the crosslinker concentration and the level of plasticizer.
  • This example relates to the production of films according to the invention with a second cross-linking step after stretching, whereby the physiological degradation times of the films are markedly prolonged.
  • This example relates to the preparation of a gelatin-based film wherein the crosslinking has been carried out enzymatically with transglutaminase.
  • pig skin gelatin Bloom strength 300 g
  • plasticizer of about 29 wt.% Dissolved in a mixture of 72 g water and 8 g of glycerin at 60 0 C.
  • 4 g of an aqueous transglutaminase solution having a specific activity of 30 U / g was added, and the mixture is homogenized in a thickness of 1 mm squeegeed on a tempered at 45 0 C lenunterlage polyethylene.
  • the film was peeled off from the PE base, held for 2 hours at a temperature of 50 ° C. and a relative atmospheric humidity of 90% and then for about two days at a temperature of 25 ° C. and a relative humidity of 30%. dried.
  • the transglutaminase crosslinked film had a tensile strength of about 9 N / mm 2 at an elongation at break of about 300%.
  • a stretching of the film produced in this way and optionally a second crosslinking with formaldehyde in the gas phase can be carried out in the same manner as described in Examples 1 and 3, respectively.
  • the inventive stretching of hollow cylinders based on gelatin made it possible to produce very thin tubes with an inner diameter in the range from 800 to 1200 ⁇ m.
  • the starting material was a solution of pork rind gelatin (Bloom strength 300 g), which was prepared according to the procedure described in Examples 1 and 2 by dissolving 100 g of gelatin in a mixture of 260 g of water and 40 g of glycerol as plasticizer. This corresponds to a plasticizer content of about 29% by weight.
  • the Gelatinerschreibchen formed could be removed from the stainless steel pins. These were then stored for another five days at 23 0 C and a relative humidity of 45%. For stretching, the tubes were clamped at both ends and softened under the action of hot steam. In this thermoplastic state they were elongated with a draw ratio of about 1.4, fixed in this state and dried overnight at 23 0 C and a relative humidity of 45%.
  • the gelatin tubes were subjected to a second cross-linking step according to the films described in Example 3.
  • the tubes were exposed to the equilibrium vapor pressure of a 17% by weight aqueous formaldehyde solution at room temperature in a desiccator for 17 hours. In this case, both ends of the tubes were sealed, so that the crosslinking took place substantially only from the outside.
  • FIG. 7 shows some of the gelatin tubes 10 produced in this way with a length of approximately 3 cm in a glass vessel 12.
  • FIG. 8 shows a light micrograph of the cross section through one of the tubes.
  • the tube shown has an inner diameter of about 1100 microns and a wall thickness of about 200 microns: Both the cross-sectional shape and the wall thickness of the tube are extremely regular.
  • the Gelatinerschreibchen produced in this example are particularly well suited for use as Nervenleitschienen due to their dimensions and because of their long degradation times. Also, the stronger cross-linking of the tubes from the outside is advantageous for this application, since in this way the tube can be degraded from the inside as the nerve cell grows.
  • By increasing the draw ratio it is also possible to produce hollow cylinders according to the invention with an even smaller inside diameter, which may be advantageous for other applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Selon l'invention, grâce à l'amélioration des taux d'étirage, des cylindres creux présentant une diamètre interne encore plus petit peuvent être produits, cela pouvant être très avantageux pour d'autres utilisations. Lors de l'utilisation du procédé de l'invention, il est possible de produire des petits tuyaux extrêmement fins et présentant un diamètre de l'ordre de 150 νm. Une telle valeur ne peut pas être obtenue sans étirage du petit tuyau.
EP06818566A 2005-11-17 2006-11-16 Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes Not-in-force EP1948257B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005054938A DE102005054938A1 (de) 2005-11-17 2005-11-17 Formkörper auf Basis eines vernetzten, Gelatine enthaltenden Materials, Verfahren zu deren Herstellung sowie deren Verwendung
PCT/EP2006/010973 WO2007057176A1 (fr) 2005-11-17 2006-11-16 Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes

Publications (2)

Publication Number Publication Date
EP1948257A1 true EP1948257A1 (fr) 2008-07-30
EP1948257B1 EP1948257B1 (fr) 2009-07-22

Family

ID=37872408

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06818566A Not-in-force EP1948257B1 (fr) 2005-11-17 2006-11-16 Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes

Country Status (12)

Country Link
US (1) US20080254088A1 (fr)
EP (1) EP1948257B1 (fr)
JP (1) JP2009516038A (fr)
KR (1) KR20080069182A (fr)
CN (1) CN101312753A (fr)
AU (1) AU2006314767A1 (fr)
BR (1) BRPI0618681A2 (fr)
CA (1) CA2629802A1 (fr)
DE (2) DE102005054938A1 (fr)
DK (1) DK1948257T3 (fr)
ES (1) ES2328282T3 (fr)
WO (1) WO2007057176A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006033167A1 (de) 2006-07-10 2008-01-24 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
DE102006033168A1 (de) * 2006-07-10 2008-01-17 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung einer vernetzenden therapeutischen Zusammensetzung
DE102008054245A1 (de) * 2008-10-24 2010-04-29 Aesculap Ag Fixierungselement zum Fixieren von Gewebe und/oder Implantaten
JP5828643B2 (ja) * 2011-02-14 2015-12-09 学校法人 関西大学 ゼラチン水溶液を用いた弾性に富む繊維ならびに中空糸の乾式紡糸法
CN102286204B (zh) * 2011-04-28 2012-09-12 东北林业大学 以废纸纤维和废弃皮革胶原合成复合材料的制备方法
CN103893827B (zh) * 2014-04-21 2016-05-25 陕西巨子生物技术有限公司 一种增强生物相容性的人工骨支架材料及其制备方法
WO2017064190A1 (fr) 2015-10-13 2017-04-20 Sanofi Pasteur Compositions immunogènes contre s. aureus
CN105879112B (zh) * 2016-04-21 2019-02-19 四川大学 一种促神经修复管及其制备方法和应用
WO2021241409A1 (fr) * 2020-05-25 2021-12-02 富士フイルム株式会社 Composition, corps moulé en forme de feuille, cuir artificiel, et procédé de production de corps moulé en forme de feuille

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US660840A (en) * 1899-06-23 1900-10-30 Samuel Wesley Butterfield Sawmill set-works.
DE4007668A1 (de) * 1990-03-10 1991-09-12 Beiersdorf Ag Hydrogelschaeume und verfahren zu deren herstellung
DK0621775T3 (da) * 1992-01-17 1997-10-06 Alfatec Pharma Gmbh Peptidlægemiddelholdige pellets, deres fremstilling og anvendelse.
JP3545148B2 (ja) * 1996-01-08 2004-07-21 味の素株式会社 食用マイクロカプセル及びそれを含有する食品
WO1998019718A1 (fr) * 1996-11-05 1998-05-14 Challenge Bioproducts Co., Ltd. Modification chimique de materiaux biomedicaux par la genipine
TW528600B (en) * 1996-11-20 2003-04-21 Yasuhiko Shimizu Artificial neural canal
DE19704737A1 (de) * 1997-02-07 1998-08-13 Kalle Nalo Gmbh Eßbare Formkörper, insbesondere Flach- und Schlauchfolien
JPH1133104A (ja) * 1997-07-16 1999-02-09 Res Inst For Prod Dev 生体組織への接着性を有する医用材料
JP3502272B2 (ja) * 1997-09-01 2004-03-02 株式会社ジェイ・エム・エス 生体組織接着性医用材料及びその製造法
JP4198394B2 (ja) * 2001-06-15 2008-12-17 グンゼ株式会社 癒着防止材
JP4295482B2 (ja) * 2002-08-08 2009-07-15 グンゼ株式会社 癒着防止材
KR100803798B1 (ko) * 2002-12-16 2008-02-14 군제 가부시키가이샤 의료용 필름
JP4554916B2 (ja) * 2002-12-16 2010-09-29 グンゼ株式会社 医療用フィルム
DE10305799B4 (de) * 2003-02-12 2012-12-27 Henkel Ag & Co. Kgaa Verfahren zur Herstellung eines blasgeformten Waschmittelkörpers
DE102004024635A1 (de) * 2004-05-12 2005-12-08 Deutsche Gelatine-Fabriken Stoess Ag Verfahren zur Herstellung von Formkörpern auf Basis von vernetzter Gelatine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007057176A1 *

Also Published As

Publication number Publication date
DK1948257T3 (da) 2009-08-31
JP2009516038A (ja) 2009-04-16
CA2629802A1 (fr) 2007-05-24
ES2328282T3 (es) 2009-11-11
EP1948257B1 (fr) 2009-07-22
BRPI0618681A2 (pt) 2011-09-06
CN101312753A (zh) 2008-11-26
US20080254088A1 (en) 2008-10-16
DE102005054938A1 (de) 2007-05-24
WO2007057176A1 (fr) 2007-05-24
DE502006004340D1 (de) 2009-09-03
KR20080069182A (ko) 2008-07-25
AU2006314767A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
EP1948257B1 (fr) Corps moule a fabrique a partir d'un materiau reticule, contenant de la gelatine, procede de production et d'utilisation associes
DE69918714T2 (de) Herstellung von kollagenmaterial mit in vivo kontrollierter bioabbaubarkeit
EP1948263B1 (fr) Tuyaux de guidage pour les nerfs
EP1948260B8 (fr) Materiau composite utilise en particulier en medecine et procede de production associe
EP1747247A2 (fr) Procede de production de corps moules a base de gelatine reticulee
DE69729314T2 (de) Kollagenlaminat material und verfahren zu dessen herstellung
DE1491218C3 (de) Blutgefäßprothese und Verfahren zur Herstellung derselben
DE102006033167A1 (de) Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
DE102004022645A1 (de) Bioresorbierbares Material auf Kollagen-Basis
EP2098255B1 (fr) Procédé de fabrication de matériau collagène
EP1957125B1 (fr) Procede pour produire un profile creux au moyen d'un materiau reticule et gelatineux, et implants se presentant sous la forme de profiles creux
DE19948120C2 (de) 3D-Matrix zur Herstellung von Zelltransplantaten
EP1385559B9 (fr) Matrices poreuses et non poreuses a base de chitosane et d'acides hydroxycarboxyliques
DE102008013091A1 (de) Verfahren zur Herstellung von Kollagen-Material, Kollagen-Material
EP1506026A2 (fr) Utilisation de produits a base de chitosan
DE102005054937A1 (de) Angiogenese förderndes Substrat
DE102007024239A1 (de) Angiogenese förderndes Substrat
DE10246816A1 (de) Verwendung von Chitosanmaterialien
WO2004091678A1 (fr) Film de chitosane utilise en remplacement de perioste
DE102008054245A1 (de) Fixierungselement zum Fixieren von Gewebe und/oder Implantaten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 502006004340

Country of ref document: DE

Date of ref document: 20090903

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2328282

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091122

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20091111

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091022

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

BERE Be: lapsed

Owner name: GELITA A.G.

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

26N No opposition filed

Effective date: 20100423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091023

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20101125

Year of fee payment: 5

Ref country code: FR

Payment date: 20101203

Year of fee payment: 5

Ref country code: IE

Payment date: 20101123

Year of fee payment: 5

Ref country code: NL

Payment date: 20101125

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20101126

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101123

Year of fee payment: 5

Ref country code: GB

Payment date: 20101117

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091116

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20101221

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101201

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120601

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120601

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111116

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502006004340

Country of ref document: DE

Effective date: 20120601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111116

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111116

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 436967

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120601

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111117